Avita Medical Reports Positive Results from Randomized, Multicentre EU Study of ReGenerCell™

Avita Medical Ltd, (ASX:AVH, OTCQX:AVMXY) reported positive results from the Company’s multicentre clinical trial of ReGenerCell™ in the treatment of chronic Venous Leg Ulcers (VLUs). In the seven-centre, 52-patient randomized study, ReGenerCell demonstrated statistically significant improvements in key measures of wound healing, pain and quality of life.
According to the news:

In addition to significant decreases in wound size, patients in the ReGenerCell™ group reported significant drops of nearly 2 points on a 10-point pain rating scale two weeks after treatment (p=0.017), as compared to the control group, which showed no decrease in pain after two weeks. As a quality of life measure, the Charing Cross Venous Leg Ulcer Questionnaire showed consistent improvements in the evaluated areas of social interaction, domestic activity, emotional status and cosmesis, and again, despite the small sample size, statistical significance was shown on the emotional status portion of the questionnaire (p=0.044).

Avita CEO, Adam Kelliher commented:

Our favorable results in larger ulcers, notably halving the healing time, means our approach could really help those with the hardest wounds to heal, and reduce costs at a time of health budget challenges. The positive effects seen across the treated group are very encouraging, given the complexity and challenge presented by chronic venous leg ulcers.

Click here to view the full press release.